OTCMKTS:PPCB Propanc Biopharma 2/20/2024 Earnings Report $4.15 0.00 (0.00%) As of 06/27/2025 ProfileEarnings History Propanc Biopharma EPS ResultsActual EPS-$0.03Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APropanc Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APropanc Biopharma Announcement DetailsQuarterDate2/20/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Propanc Biopharma Earnings HeadlinesPropanc Biopharma Issues Promissory Note for CapitalJune 2, 2025 | tipranks.comPropanc Biopharma Inc (PPCB)August 21, 2024 | investing.comWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His administration has begun to fast-track the operations of a handful of companies… Accelerating their potential profits. | InvestorPlace (Ad)Propanc Biopharma Receives Notice of Allowance for "Proenzyme Composition" Patent in North AmericaAugust 14, 2024 | finance.yahoo.comVTXB Vortex Brands Co.May 29, 2024 | seekingalpha.comPropanc Biopharma, Inc. (PPCB)May 29, 2024 | finance.yahoo.comSee More Propanc Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Propanc Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Propanc Biopharma and other key companies, straight to your email. Email Address About Propanc BiopharmaPropanc Biopharma (OTCMKTS:PPCB) Ltd. (OTCMKTS:PPCB) is a clinical‐stage biotechnology company focused on developing novel proenzyme‐based therapeutics for the treatment of pancreatic cancer and other solid tumors. The company’s lead candidate, PRP, combines recombinant proteases designed to disrupt tumor stroma and enhance the efficacy of standard chemotherapies, aiming to improve patient outcomes and quality of life. Propanc also continues to advance its pipeline by exploring additional proenzyme formulations and delivery methods to address unmet medical needs across various oncology indications.Written by Jeffrey Neal JohnsonView Propanc Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
